GAS5 and Miyoshi myopathy: To establish <i>GAS5</i> as a robust biomarker in MM, future studies should focus on larger patient cohorts to validate its expression within the bone marrow niche and its specific association with high-risk 'double-hit' cytogenetic aberrations and glucocorticoid resistance.